Description
Indications of Konakion 10 mg/ml
Konakion 10 mg/ml (Vitamin K-1) is indicated in following indications- Prophylaxis and treatment of haemorrhagic disease in the newborn. Haemorrhage or risk of haemorrhage as a result of severe hypoprothrombinemia (i.e. deficiency of clotting factors II, VII, IX and X) of various etiologies, including overdosage of courmarin-type anticoagulants, their combination with phenylbutazone, and other forms of hypovitaminosis K (e.g. in obstructive jaundice as well as liver and intestinal disorders, and after prolonged treatment with antibiotics, sulphonamides or salicylates). Prevention and treatment of bleeding due to vitamin K deficiency.
Theropeutic Class
Vitamin-K Preparations
Pharmacology
Konakion 10 mg/ml is a procoagulant factor. As a component of a hepatic carboxylase system, Konakion 10 mg/ml is involved in the post translational carboxylation of clotting factors II (prothrombin), VII, IX and X and the clotting inhibitors protein C and protein S. Konakion 10 mg/ml is ineffective in hereditary hypoprothrombinemia or hypoprothrombinemia induced by severe hepatic failure. Lack of Konakion 10 mg/ml leads to an increased tendency to haemorrhagic disease in the newborn. Konakion 10 mg/ml administration, which promotes synthesis of the above-mentioned coagulation factors by the liver, can reverse an abnormal coagulation status and bleeding due to Konakion 10 mg/ml deficiency.
Dosage & Administration of Konakion 10 mg/ml
Prophylaxis: Mild Hemorrhage or hemorrhagic tendency: The usual dose for Neonates is 2 mg orally at or just after birth. Then 2 mg on 4th-5th day and another 2 mg on 28th-30th day orally. If the oral route is unsuitable then 2 mg of drug can be administered by IM or IV route. Children over 1 year of age: Could be given 5-10 mg orally. A single 1 mg (0.1 ml) dose IM is recommended in children who are not assured of receiving a second oral dose or, in the case of breast-fed children, who are not assured of receiving a third oral dose.Therapy: Initially, 1 mg by intravenous injection, with further doses as required, based on the clinical picture and coagulation status. Neonates with special risk factors: Pre-maturity, birth asphyxia (inadequate intake of oxygen by the baby during birth process), obstructive jaundice, inability to swallow, maternal use of anticoagulants or anti-epileptics- 1 mg intramuscularly or intravenously at birth or shortly after birth if the oral route is unsuitable. Intramuscular and intravenous doses should not exceed 0.4 mg/kg in premature infants weighing less than 2.5 kg. The size and frequency of further doses should be based on coagulation status To ensure a total protection of the newborns, 3 prophylactic doses of Vitamin K should be administered orally following the dosing schedule mentioned above.
Interaction of Konakion 10 mg/ml
Konakion 10 mg/ml antagonises the effect of coumarin-type anticoagulants. Coadministration of anticonvulsants can impair the action of vitamin K-1.
Contraindications
It is contraindicated in patients with known hypersensitivity to any of its constituents.
Side Effects of Konakion 10 mg/ml
There are isolated unconfirmed reports on the possible occurrence of anaphylactoid reactions and venous irritation or phlebitis after parenteral use of Konakion 10 mg/ml injections.
Precautions & Warnings
Careful monitoring of the coagulation parameters is necessary for patients with severely impaired liver function after administration of Konakion 10 mg/ml .
Storage Conditions
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.





Reviews
There are no reviews yet.